0000899243-22-023336.txt : 20220621
0000899243-22-023336.hdr.sgml : 20220621
20220621160600
ACCESSION NUMBER: 0000899243-22-023336
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220616
FILED AS OF DATE: 20220621
DATE AS OF CHANGE: 20220621
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Waksal Harlan
CENTRAL INDEX KEY: 0001449008
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39273
FILM NUMBER: 221028164
MAIL ADDRESS:
STREET 1: WAKSAL CONSULTING LLC
STREET 2: 7 NORTH WILLOW STREET, SUITE 6
CITY: MONTCLAIR
STATE: NJ
ZIP: 07042
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Lyra Therapeutics, Inc.
CENTRAL INDEX KEY: 0001327273
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 480 ARSENAL WAY
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 617-373-4600
MAIL ADDRESS:
STREET 1: 480 ARSENAL WAY
CITY: WATERTOWN
STATE: MA
ZIP: 02472
FORMER COMPANY:
FORMER CONFORMED NAME: 480 Biomedical, Inc.
DATE OF NAME CHANGE: 20120927
FORMER COMPANY:
FORMER CONFORMED NAME: Arsenal Vascular, Inc.
DATE OF NAME CHANGE: 20110826
FORMER COMPANY:
FORMER CONFORMED NAME: Arsenal Medical, Inc.
DATE OF NAME CHANGE: 20090414
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-06-16
0
0001327273
Lyra Therapeutics, Inc.
LYRA
0001449008
Waksal Harlan
C/O LYRA THERAPEUTICS, INC.
480 ARSENAL WAY
WATERTOWN
MA
02472
1
1
0
0
Executive Chair
Stock Option
5.09
2022-06-16
4
A
0
953002
0.00
A
2032-06-15
Common Stock
953002
953002
D
On June 16, 2022, the Reporting Person was granted an option to purchase 953,002 shares of common stock. The option vests and becomes exercisable as to 317,667 shares underlying the option when the Issuer's market capitalization reaches $250,000,000; (ii) 317,667 shares underlying the option when the Issuer's market capitalization reaches $350,000,000; and (iii) 317,668 shares underlying the option when the Issuer's market capitalization reaches $500,000,000, all subject to the Reporting Person's continued service to the Issuer through each such date.
/s/ Jason Cavalier, Attorney-in-Fact for Harlan Waksal, M.D.
2022-06-21